Figure 5. Illustration showing the major findings suggested by the results of the present study.

antiapoptotic protein Bcl-2 was inhibited in the RVLM of SHRSP. Neuronal apoptosis is mediated by caspase-3 activated by Bax and Bad and inhibited by Bcl-2 in mitochondria.[1] Activation of caspase-3 induces neuronal apoptosis.[18,19] Other reports indicate that p38 MAPK and ERK activate caspase-3–dependent neuronal apoptosis.[8] We previously demonstrated that mitochondria-derived ROS mediate sympathoexcitation induced by angiotensin II in the RVLM,[40] and these results suggest that mitochondrial dysfunction in the RVLM causes sympathoexcitation via ROS production. We hypothesized that Ras, p38 MAPK, and ERK activate the mitochondrial apoptotic pathway and inhibit the mitochondrial antiapoptotic pathway and that caspase-3–dependent neuronal apoptosis is activated in the RVLM of SHRSP. The possibility of caspase-3–independent neuronal apoptosis in the RVLM or of a direct link between ROS and caspase-3 activation was not examined in the present study. A previous report suggested that neural apoptosis in the RVLM leads to a reduction of sympathetic outflow.[40] Further study is necessary to determine the reasons for this discrepancy.

In the present study, we determined the ICV infusion dose of the Ras or caspase-3 inhibitor that inhibits blood pressure, HR, and SNA. There were dose-dependent effects of the Ras and caspase-3 inhibitors on blood pressure and HR (data not shown). Furthermore, the doses of Ras or caspase-3 inhibitor used in the present study did not change blood pressure or HR when injected intravenously (data not shown). In addition, Ras and caspase-3 activity were significantly higher in SHRSP than in WKY, and the depressor and sympathoinhibitory effects of Ras and caspase-3 inhibitors were also significantly greater in SHRSP than in WKY. Thus, we consider that the doses of Ras and caspase-3 inhibitor used in the present study were reasonable to inhibit Ras or caspase-3 activity in the RVLM. Future studies, however, are needed to investigate the effects of inhibiting Ras and caspase-3 activity specifically in the RVLM.

Interestingly, JNK was not altered in the RVLM of SHRSP. JNK is an upstream activator of apoptosis. In a heart failure model, JNK is upregulated in the RVLM.[41] Angiotensin II and NAD(P)H oxidase-derived superoxide anions, however, do not activate JNK in the RVLM,[27] and these findings are consistent with the present results. We did not explore the mechanisms of this discrepancy in the present study and are therefore not able to exclude the importance of JNK in the RVLM for cardiovascular regulation. JNK in the RVLM might be significantly activated in heart failure progressing to hypertension. Furthermore, we did not examine the protein kinase C–dependent pathway in the RVLM. A previous report indicates that protein kinase C–dependent translocation of Bax in the RVLM initiates caspase-3–dependent apoptosis during experimental endotoxemia.[28] It is possible that this pathway is also a major pathway involved in the increase in SNA in SHRSP.

The present study has some limitations. Ras activity in the RVLM was inhibited by ICV infusion of the Ras inhibitor, and the inhibition of Ras activity was not limited to the RVLM; therefore, we cannot exclude the possible effects of Ras inhibition in other brain sites, and our results do not suggest that the $AT_1R/Ras/caspase-3$ pathway in the RVLM is the only major pathway of the sympathetic control. Moreover, none of the ICV antagonists completely normalized BP, HR, and SNA in SHRSP. Many factors in the RVLM may be involved in changing SNA. Nevertheless, Ras activity was inhibited in the RVLM, and, therefore, the neural activity of the RVLM directly influenced SNA.[23,24] Furthermore, we found that the pressor effect evoked by microinjection of angiotensin II into the RVLM was attenuated in SHRSP treated with ICV infusion of the Ras inhibitor. Previous reports suggest that activation of the brain angiotensin system contributes to the neural mechanisms of hypertension.[23,24,42–45] In addition, a renin-angiotensin system also exists inside the blood-brain barrier.[42,46] All components of the renin-angiotensin system are present in the brain, such as renin, angiotensinogen, angiotensin-converting enzyme, angiotensin II, and AT_1 and angiotensin type 2 (AT_2) receptors.[45] Importantly, AT_1 receptors are richly distributed in the paraventricular nucleus of the hypothalamus, nucleus tractus solitarius, and RVLM, which are involved in autonomic cardiovascular regulation.[42,44–46] Therefore, it is conceivable that alteration of a signaling pathway in the RVLM influences central sympathetic outflow via AT_1R in the RVLM of SHRSP, although we cannot exclude the possible interaction of other autonomic nuclei, such as the paraventricular nucleus of the hypothalamus. The findings of the present study do not exclude the possibility that similar effects might occur in other nuclei or that these findings are indirect effects. In this regard, further study is necessary to determine the role of other autonomic nuclei in neural control of blood pressure. It would be interesting if we could examine the direct effect of chronic infusion of a Ras inhibitor and/or a caspase inhibitor directly into the RVLM. In addition, we did not measure SNA directly in the present study because chronic direct measurement of SNA is technically difficult. We examined SNA by measuring 24-hour uNE and spectral analysis of systolic blood pressure. uNE is considered to be a measure of SNA,[20,47] and measurement of uNE is often used to assess SNA in small awake animals.[47] We consider that uNE and LFnuSBP are appropriate parameters for assessing SNA.

In conclusion, AT_1R-induced activation of caspase-3 through Ras/p38 MAPK/ERK and the mitochondrial apoptotic pathway in the RVLM of SHRSP increases blood pressure, HR, and SNA

and decreases BRS in SHRSP. Inhibition of this pathway by ARB in the RVLM may be a novel therapeutic approach to sympathoexcitation in hypertension.

Perspectives

Our results suggest that Ras-activated caspase-3, acting through the p38 MAPK, ERK, and mitochondrial apoptotic pathways in the RVLM, increases SNA. Previous studies indicate that angiotensin II and ROS produced by NAD(P)H oxidase are upstream of Ras. In the RVLM, angiotensin II and ROS are important modulating factors regulating SNA, which is involved in cardiovascular disease, such as hypertension and heart failure. We consider that neural apoptosis in the RVLM is a novel target for the treatment of cardiovascular diseases exhibiting increased SNA.

Disclosures

None.

References

1. Buss RR, Oppenheim RW. Role of programmed cell death in normal neuronal development and function. *Anat Sci Int.* 2004;79:191–197.
2. Lossi L, Merighi A. In vivo cellular and molecular mechanisms of neuronal apoptosis in the mammalian CNS. *Prog Neurobiol.* 2003;69: 287–312.
3. De Zio D, Giunta L, Corvaro M, Ferraro E, Cecconi F. Expanding roles of programmed cell death in mammalian neurodevelopment. *Semin Cell Dev Biol.* 2005;16:281–294.
4. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. *Arterioscler Thromb Vasc Biol.* 2000;20:2175–2183.
5. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. Mitogen-activated protein kinase pathways; regulation and physiological functions. *Endocr Rev.* 2001;22:153–183.
6. Mielke K, Herdegen T. JNK and p38 stress kinase-degenerative effectors of signal-transduction-cascade in the nervous system. *Prog Neurobiol.* 2000;61:45–60.
7. Harper SJ, LoGrasso P. Signalling for survival and death in neurons: the role of stress-activated kinases, JNK and p38. *Cell Signal.* 2001;13: 299–310.
8. Cheng A, Chan SL, Milhavet O, Wang S, Mattson MP. p38 MAP kinase mediates nitric oxide-induced apoptosis of neural progenitor cells. *J Biol Chem.* 2001;276:43320–43327.
9. Hunter T. Oncoprotein networks. *Cell.* 1997;88:333–346.
10. Lloyd AC, Obermuller F, Staddon S, Barth CF, McMahon M, Land H. Cooperating oncogenes converge to regulate cyclin/cdk complexes. *Genes Dev.* 1997;11:663–677.
11. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. *Cell.* 1997;88:593–602.
12. Shao J, Sheng H, DuBois RN, Beauchamp RD. Oncogenic Ras-mediated cell growth arrest and apoptosis are associated with increased ubiquitin-dependent cyclin D1 degradation. *J Biol Chem.* 2000;275:22916–22924.
13. Chen CY, Liou J, Forman LW, Faller DV. Differential regulation of discrete apoptotic pathways by Ras. *J Biol Chem.* 1998;273:16700–16709.
14. Nesterov A, Nikrad M, Johnson T, Kraft AS. Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-alpha related apoptosis-inducing ligand-induced apoptosis. *Cancer Res.* 2004;64:3922–3927.
15. Downward J. PI 3-kinase, Akt and cell survival. *Semin Cell Dev Biol.* 2004;15:177–182.
16. Choi JA, Park MT, Kang CM, Um HD, Bae S, Lee KH, Kim TH, Kim JH, Cho CK, Lee YS, Chung HY, Lee SJ. Opposite effects of Ha-Ras and Ki-Ras on radiation-induced apoptosis via differential activation of PI3K/Akt and Rac/p38 mitogen-activated protein kinase signaling pathways. *Oncogene.* 2004;23:9–20.
17. Predescu SA, Predescu DN, Knezevic I, Klein IK, Malik AB. Intersectin-1s regulates the mitochondrial apoptotic pathway in endothelial cells. *J Biol Chem.* 2007;282:17166–17178.
18. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. *Annu Rev Biochem.* 1999;68:383–424.
19. Baydas G, Reiter RJ, Akbulut M, Tuzcu M, Tamer S. Melatonin inhibits neural apoptosis induced by homocysteine in hippocampus of rats via inhibition of cytochrome c translocation and caspase-3 activation and by regulating pro- and anti-apoptotic protein levels. *Neuroscience.* 2005;135: 879–886.
20. Kishi T, Hirooka Y, Kimura Y, Ito K, Shimokawa H, Takeshita A. Increased reactive oxygen species in rostral ventrolateral medulla contribute to neural mechanisms of hypertension in stroke-prone spontaneously hypertensive rats. *Circulation.* 2004;109:2357–2362.
21. Peterson JR, Sharma RV, Davisson RL. Reactive oxygen species in the neuropathogenesis of hypertension. *Curr Hypertens Rep.* 2006;8: 232–241.
22. Hirooka Y. Role of reactive oxygen species in brainstem in neural mechanisms of hypertension. *Auton Neurosci.* 2008;142:20–24.
23. Dampney RA, Coleman MJ, Fontes MA, Hirooka Y, Horiuchi J, Li YW, Polson JW, Potts PD, Tagawa T. Central mechanisms underlying short- and long-term regulation of the cardiovascular system. *Clin Exp Pharmacol Physiol.* 2002;29:261–268.
24. Guyenet PG. The sympathetic control of blood pressure. *Nat Rev Neurosci.* 2006;7:335–346.
25. Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats. *Jpn Circ J.* 1963;27:282–293.
26. Zimmerman MC, Dunlay RP, Lazartigues E, Zhang Y, Sharma RV, Engelhardt JF, Davisson RL. Requirement for Rac1-dependent NADPH oxidase in the cardiovascular and dipsogenic actions of angiotensin II in the brain. *Circ Res.* 2004;95:532–539.
27. Chan SH, Hsu KS, Huang CC, Wang LL, Ou CC, Chan JY. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced pressor effect via activation of p38 mitogen-activated protein kinase in the rostral ventrolateral medulla. *Circ Res.* 2005;97:772–780.
28. Chan JY, Chang AY, Wang LL, Ou CC, Chan SH. Protein kinase c-dependent mitochondrial translocation of proapoptotic protein Bax on activation of inducible nitric oxide synthase in rostral ventrolateral medulla mediates cardiovascular depression during experimental endotoxemia. *Mol Pharmacol.* 2007;71:1129–1139.
29. Braga VA, Burmeister MA, Sharma RV, Davisson RL. Cardiovascular responses to peripheral chemoreflex activation and comparison of different methods to evaluate baroreflex gain in conscious mice using telemetry. *Am J Physiol.* 2008;295:R1168–R1174.
30. Goldberg L, Haklai R, Bauer V, Heiss A, Kloog Y. New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models. *J Med Chem.* 2009;52:197–205.
31. Stepanichev MY, Kudryashova IV, Yakovlev AA, Onufriev MV, Khaspekov LG, Lyzhin AA, Lazareva NA, Gulyaeva NV. Central administration of a caspase inhibitor impairs shuttle-box performance in rats. *Neuroscience.* 2005;136:579–591.
32. Yamazato M, Ohya Y, Nakamoto M, Sakima A, Tagawa T, Harada Y, Nabika T, Takishita S. Sympathetic hyperreactivity to air-jet stress in the chromosome 1 blood pressure quantitative trait locus congenic rats. *Am J Physiol.* 2006;290:R709–R714.
33. Touyz RM, He G, El Mabrouk M, Diep Q, Mardigyan V, Schiffrin EL. Differential activation of extracellular signal-regulated protein kinase 1/2 and p38 mitogen-activated-protein kinase by At1 receptors in vascular smooth muscle cells from Wister-Kyoto rats and spontaneously hypertensive rats. *J Hypertens.* 2001;19:553–559.
34. Viedt C, Soto U, Krieger-Brauer HI, Fei J, Elsing C, Kubler W, Kreuzer J. Differential activation of mitogen-activated protein kinase in smooth muscle cells by angiotensin II: involvement of p22phox and reactive oxygen species. *Arterioscler Thromb Vasc Biol.* 2000;20: 940–948.

35. Touyz RM, Cruzado M, Tabet F, Yao G, Salomon S, Schiffrin EL. Redox-dependent AMP kinase signaling by Ang II in vascular smooth muscle cells: role of receptor tyrosine kinase transactivation. *Can J Physiol Pharmacol.* 2003;81:159–167.

36. Izumi Y, Kim S, Zhan Y, Namba M, Yasumoto H, Iwao H. Important role of angiotensin II-mediated c-Jun NH2-terminal kinase activation in cardiac hypertrophy in hypertensive rats. *Hypertension.* 2000;36: 511–516.

37. Zhang GX, Kimura S, Nishiyama A, Shokoji T, Rahman M, Abe Y. ROS during the acute phase of Ang II hypertension participates in cardiovascular MAPK activation but not vasoconstriction. *Hypertension.* 2004;43: 117–124.

38. Kuster GM, Siwik DA, Pimentel DR, Colucci WS. Role of reversible, thioredoxin-sensitive oxidative protein modifications in cardiac myocytes. *Antioxid Redox Signal.* 2006;8:2153–2159.

39. McDermott EP, O'Neill LA. Ras participates in the activation of p38 MAPK by interleukin-1 by associating with IRAK, IRAK2, TRAF6, and TAK-1. *J Biol Chem.* 2002;277:7808–7815.

40. Nozoe M, Hirooka Y, Koga Y, Araki S, Konno S, Kishi T, Ide T, Sunagawa K. Mitochondria-derived reactive oxygen species mediate sympathoexcitation induced by angiotensin II in the rostral ventrolateral medulla. *J Hypertens.* 2008;26:2176–2184.

41. Liu D, Gao L, Roy SK, Cornish KG, Zucker IH. Neuronal angiotensin II type 1 receptor upregulation in heart failure: activation of activator protein 1 and Jun N-terminal kinase. *Circ Res.* 2006;99:1004–1011.

42. Phillips MI, Sumners C. Angiotensin II in central nervous system physiology. *Regul Pept.* 1998;78:1–11.

43. Pilowsky PM, Goodchild AK. Baroreceptor reflex pathways and neurotransmitters: 10 years on. *J Hypertens.* 2002;20:1675–1688.

44. McKinley MJ, Albiston AL, Allen AM, Mathai ML, May CN, McAllen RM, Oldfield BJ, Mendelsohn FA, Chai SY. The brain renin-angiotensin system: location and physiological roles. *Int J Biochem Cell Biol.* 2003; 35:901–918.

45. Saavedra JM. Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities. *Cell Mol Neurobiol.* 2005;25: 485–512.

46. Seltzer A, Bregonzio C, Armando I, Baiardi G, Saavedra JM. Oral administration of an AT1 receptor antagonist prevents the central effects of angiotensin II in spontaneously hypertensive rats. *Brain Res.* 2004; 1028:9–18.

47. Xie T, Plagge A, Gavrilova O, Pack S, Jou W, Lai EW, Frontera M, Kelsey G, Weinstein LS. The alternative stimulatory G protein α-subunit XLαs is a critical regulator of energy and glucose metabolism and sympathetic nerve activity in adult mice. *J Biol Chem.* 2006;281: 18989–18999.

AT₁ Receptor-Activated Caspase-3 through Ras/MAPK/ERK in the RVLM Is Involved in the Sympathoexcitation in SHRSP

Takuya Kishi, Yoshitaka Hirooka, Satomi Konno, Kiyohiro Ogawa, Kenji Sunagawa

From the Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

Short title: Ras and Apoptosis in Brain Increases SNA

Correspondence to Yoshitaka Hirooka, MD, PhD, FAHA
Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. Phone: +81-92-642-5360; Fax: +81-92-642-5374; E-mail: hyoshi@cardiol.med.kyushu-u.ac.jp

Supplemental Methods

This study was reviewed and approved by the Committee on the Ethics of Animal Experiments at the Kyushu University Graduate School of Medical Sciences and conducted according to the Guidelines for Animal Experiments of Kyushu University.

Animals and General Procedures

Male SHRSP/Izm rats and age-matched Wistar-Kyoto (WKY) rats (14-16 weeks-old; SLC Japan, Hamamatsu, Japan), fed standard feed, were divided into seven groups (SHRSP treated with Ras inhibitor, S-RI; SHRSP treated with caspase-3 inhibitor, S-CI; SHRSP treated with an angiotensin receptor blocker [ARB], S-ARB; SHRSP treated with vehicle, S-Veh; WKY treated with Ras inhibitor, W-RI; WKY treated with caspase-3 inhibitor, W-CI; and WKY with vehicle, W-Veh; n=5 for each). In the S-RI, W-RI, S-CI, W-CI, S-Veh, W-Veh, and S-ARB groups, we measured blood pressure, and heart rate (HR) using the UA-10 radiotelemetry system (Data Science International) as described previously.[1] Urinary norepinephrine concentrations were measured, and urinary norepinephrine excretion (uNE) for 24 hours was calculated as an indicator of sympathetic nerve activity (SNA), as described previously.[1, 2] Furthermore, in the S-RI, W-RI, S-CI, W-CI, S-Veh, and W-Veh groups, spectral analysis was performed using an adaptive auto-regressive model to provide power spectra for systolic blood pressure (SBP). Blood pressure was recorded for 5 minutes between 9AM and 12 PM every day, and we then determined the total power of SBP and the total spectral density of the variables. The relative value of each spectral power component was also measured and expressed in normalized units. The low frequency (LF) power of SBP was computed by integrating the spectra between 0.04 and 0.15 Hz, and SNA was calculated using the normalized unit of the LF component of SBP (LFnuSBP).[3-6] Baroreflex sensitivity (BRS) was measured using a spontaneous sequence method as a parameter of autonomic control. Sequence analysis detected sequences of three or more beats in which there was either an increase in SBP and pulse interval (PI; Up-Sequence) or a decrease in SBP and PI (Down-Sequence). BRS was estimated as the mean slope of the Up- and Down-Sequences.[7, 8]

To obtain the RVLM tissues, the rats were deeply anesthetized with sodium pentobarbital (100 mg/kg IP) and perfused transcardially with phosphate-buffered saline (PBS; 150 mol/L NaCl, 3 mmol/L KCl, and 5 nmol/L phosphate; pH 7.4, 4°C). The brains were removed quickly, and 1-mm thick sections were cut using a cryostat at -7 ± 1°C. The RVLM was defined according to a rat brain atlas, as described previously.[1]

Activity of Ras, p38 MAPK, ERK, and JNK in the RVLM

The Ras activity was determined by measuring the expression of Ras-GTP per total Ras.[9] The activities of p38 MAPK, ERK, and JNK were determined by measuring the expression of the phosphorylated form of each protein per total Ras, p38 MAPK, ERK, and JNK, respectively. The expression of phosphorylated or total RAS, p38 MAPK, ERK, and JNK in the RVLM tissue was determined by Western blot analysis.

Activity of Caspase-3 and Expression of Bax, Bad, and Bcl-2 in the RVLM

The caspase-3 activity in the cytosolic fraction of the RVLM tissues was measured using the synthetic substrate acetyl-Asp-Glu-Val-Asp-7-amido-4 methyl coumarin (Ac-DEVD-AMC), as described previously.[10] The reactions were incubated at 37°C and the release of the fluorescent

product was monitored with a spectrofluorometer using excitation and emission wavelengths of 380 and 440 nm, respectively. The expression of Bax, Bad, and Bcl-2 in the mitochondrial fraction of RVLM tissues was determined by Western blot analysis.

Intracerebroventricular Injection of Ras Inhibitor, Caspase-3 Inhibitor, and Angiotensin II Type 1 Receptor Blocker

S-Farnesylthiosalicylic acid (FTS), a specific Ras inhibitor (Calbiochem, La Jolla, CA),[11] was dissolved in dimethylsulfoxide (DMSO) and further diluted in artificial cerebrospinal fluid (aCSF) at a concentration of 1 mmol/L. N-Benzyloxycarbonyl-Asp (OMe)-Glu (OMe)-Val-Asp-(OMe)-fluoro-methylketone (Z-DEVD-FMK), a specific caspase-3 inhibitor (Calbiochem), was also dissolved in DMSO and further diluted in aCSF to a concentration of 750 μmol/L.[12] FTS, Z-DEVD-FMK, candesartan (1 μg/μl), or DMSO in aCSF as vehicle was infused at 0.5 μl/h for 14 days with an osmotic minipump (Alzet 1003D; Alza Scientific Products), the cannula of which was placed in the left ventricle (from bregma: anteroposterior, −0.8 mm; lateral, 1.5 mm; depth, 3.5 mm) of SHRSP and WKY. These doses of FTS and Z-DEVD-FMK were determined to decrease blood pressure, HR, and SNA in SHRSP. Changes in blood pressure and HR were measured in SHRSP after terminating the 14-day ICV infusion of the Ras inhibitor (n=4). The dose of candesartan used has no centrally mediated antihypertensive effect in SHR and SHRSP and blocks changes in blood pressure and HR in response to ICV infusion of angiotensin II.[13]

Microinjection of Angiotensin II into the RVLM

Telemetry was used to monitor the changes in mean blood pressure (MBP), HR, and LFnuSBP evoked by the bilateral microinjection of angiotensin II (25 pmol in 50 nL of PBS) into the RVLM of S-RI or S-VEH in anesthetized rats 14 days after beginning the ICV infusion. The microinjection procedures and the method used to verify cannula placement in the RVLM were described previously.[1]

Statistical Analysis

Normally distributed variables are expressed as mean ± SE. Unpaired t and Mann-Whitney U tests were used to compare the differences in normally distributed and non-normally distributed variables, respectively. Data were also analyzed by a two-factor repeated-measures analysis of variance. Differences were considered to be statistically significant at a P value of less than 0.05.

References

1. Kishi T, Hirooka Y, Kimura Y, Ito K, Shimokawa H, Takeshita A. Increased reactive oxygen species in rostral ventrolateral medulla contribute to neural mechanisms of hypertension in stroke-prone spontaneously hypertensive rats. *Circulation.* 2004;109:2357-2362.
2. Hirooka Y. Role of reactive oxygen species in brainstem in neural mechanisms of hypertension. *Auton Neurosci.* 2008;142:20-24.
3. Castiglioni P, Di Rienzo M, Veicsteinas A, Parati G, Merati G. Mechanisms of blood

pressure and heart rate variability: an insight from low-level paraplegia. *Am J Physiol.* 2007;292:R1502-R1509.

4. Cerutti C, Gustin MP, Paultre CZ, Lo M, Julien C, Vincent M, Sassard J. Autonomic nervous system and cardiovascular variability in rats: a spectral analysis approach. *Am J Physiol.* 1991;261:H1292–H1299.

5. Pagani M, Montano N, Porta A, Malliani A, Abboud FM, Birkett C, Somers VK. Relationship between spectral components of cardiovascular variabilities, and direct measures of muscle sympathetic nerve activity in humans. *Circulation.* 1997;95: 1441–1448.

6. Tsai ML, Shann WC, Luo WR, Yen CT. Wavelet-based analysis of low-frequency fluctuations of blood pressure and sympathetic nerve activity in rats. *Neurosci Lett.* 2004;358:165-8.

7. Waki H, Katahira K, Polson JW, Kasparov S, Murphy D, Paton JF. Automation of analysis of cardiovascular autonomic function from chronic measurements of arterial pressure in conscious rats. *Exp Physiol.* 2006;91:201-213.

8. Gonzalez-Fernandez L, Cerezo-Guisado MI, Langmesser S, Bragado MJ, Lorenzo MJ, Garcia-Marin LJ. Cleavage of focal adhesion proteins and PKCdelta during lovastatin-induced apoptosis in spontaneously immortalized rat brain neuroblasts. *FEBS J.* 2006;273:1-13.

9. Amos S, Redpath GT, Polar G, McPheson R, Schiff D, Hussaini IM. Farnesylthiosalicylic acid induces caspase activation and apoptosis in glioblastoma cells. *Cell Death Differ.* 2006;13:642-651.

10. Izumi Y, Kim S, Zhan Y, Namba M, Yasumoto H, Iwao H. Important role of angiotensin II-mediated c-Jun NH2-terminal kinase activation in cardiac hypertrophy in hypertensive rats. *Hypertension.* 2000;36:511-516.

11. Goldberg L, Haklai R, Bauer V, Heiss A, Kloog Y. New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models. *J Med Chem.* 2009;52:197-205.

12. Stepanichev MY, Kudryashova IV, Yakovlev AA, Onufriev MV, Khaspekov LG, Lyzhin AA, Lazareva NA, Gulyaeva NV. Central administration of a caspase inhibitor impairs shuttle-box performance in rats. *Neuroscience.* 2005;136:579-591.

13. Yamazato M, Ohya Y, Nakamoto M, Sakima A, Tagawa T, Harada Y, Nabika T, Takishita S. Sympathetic hyperreactivity to air-jet stress in the chromosome 1 blood pressure quantitative trait locus congenic rats. *Am J Physiol.* 2006;290:R709-R714.

Cross-Sectional Characterization of all Classes of Antihypertensives in Terms of Central Blood Pressure in Japanese Hypertensive Patients

Hiroshi Miyashita[1], Akira Aizawa[2], Junichiro Hashimoto[3], Yoshitaka Hirooka[4], Yutaka Imai[5], Yuhei Kawano[6], Katsuhiko Kohara[7], Kenji Sunagawa[4], Hiromichi Suzuki[8], Yasuharu Tabara[7], Kenji Takazawa[2], Tsuneo Takenaka[8], Hisayo Yasuda[6] and Kazuyuki Shimada[1]

BACKGROUND
Central blood pressure (CBP) has been reported to be superior to brachial blood pressure (BP) as a cardiovascular risk predictor in hypertensive patients; however, the effects of antihypertensives on CBP have not been fully examined. This cross-sectional hypothesis-generating study aimed to tentatively characterize all classes of antihypertensives in relation to CBP.

METHODS
Calibrated tonometric radial artery pressure waveforms were recorded using an automated device in 1,727 treated hypertensive patients and 848 nonhypertensive (non-HT) participants. Radial artery late systolic BP (SBP) has been reported to reflect central SBP. The difference between late and peak SBPs (ΔSBP2) was assessed with linear regression model-based adjustments. Separate regression models for ΔSBP2 were constructed for both participant groups as well as for specified sub-populations.

RESULTS
ΔSBP2 was 3.3 mm Hg lower in patients treated with any single-vasodilating (VD) antihypertensive agent without significant interclass difference than with non-VD agents, and was 2.0 mm Hg

lower than estimated in nonhypertensive subjects. Combinations of two vasodilators were 6.6 and 2.9 mm Hg lower in ΔSBP2 than nonvasodilator combinations and nonhypertensive subjects, respectively ($P < 0.001$ for all comparisons). Nonvasodilators and their combination showed high ΔSBP2, 1.1 and 3.7 mm Hg higher than in nonhypertensive subjects ($P < 0.001$ for both). Additional adjustment of the pulse rate reduced high ΔSBP2 with β-blockers (βBLs).

CONCLUSIONS
This cross-sectional observation suggests that vasodilatory antihypertensives lower CBP independently of peripheral BP levels without evident class-specific differences, whereas nonvasodilators may raise CBP.

Keywords: angiotensin receptor blockers; angiotensin-converting enzyme inhibitors; antihypertensive agents; blood pressure; calcium channel blockers; central blood pressure; diuretics; hypertension; late systolic blood pressure; nonvasodilating antihypertensive agents; pulse waveform; radial artery tonometry; vasodilating antihypertensive agents; α-blockers; β-blockers

Am J Hypertens 2010; 23:260-268 © 2010 American Journal of Hypertension, Ltd.

From the physical viewpoint, central blood pressure (CBP) more directly imposes mechanical stress on the left ventricle, large arteries and the vital organ vasculature than brachial

[1]Division of Cardiovascular Medicine, Jichi Medical University School of Medicine, Tochigi, Japan; [2]Department of Cardiology, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; [3]Department of Blood Pressure Research, Tohoku University Graduate School of Medicine, Sendai, Japan; [4]Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan; [5]Department of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences and Medicine, Sendai, Japan; [6]Division of Hypertension and Nephrology, National Cardiovascular Center, Suita, Japan; [7]Department of Geriatric Medicine, Ehime University School of Medicine, Toon-city, Japan; [8]Department of Nephrology, Saitama Medical University School of Medicine, Saitama, Japan. Correspondence: Hiroshi Miyashita (hrsm@jichi.ac.jp)

blood pressure (BP). This impact of CBP was suggested by large-scale intervention trials and population-based studies, such as the Conduit Artery Function Evaluation (CAFE) study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)[1] and Strong Heart Study (SHS).[2] In the CAFE study, only calcium channel blocker (CCB) and β-blocker (βBL)-based treatments were compared in estimated CBP. Prior to the study, several small-scale investigations assessing therapeutic alterations in CBP or aortic wave reflection had been reported.[3–11] Various theoretical explanations of the benefit of vasodilators to lower CBP have also been published;[12–14] however, only limited classes of antihypertensive drugs, such as angiotensin-converting enzyme inhibitors (ACEI) and βBL, including nitrates, have been investigated comparatively or noncomparatively. Hence, the effects of various antihypertensives on CBP are not fully understood. Randomized intervention trials are necessary to assess the effects of each antihypertensive

drug; however, it is practically difficult to directly compare all classes of antihypertensive agents at the same time in a single intervention trial. This cross-sectional observation therefore aimed to tentatively characterize all classes of antihypertensive agents commonly used in Japan in terms of CBP.

METHODS

Study design. This study was a cross-sectional observation, designed as an exploratory (or data-mining) study to generate rather than to test hypotheses.

Subjects. We enrolled 1,727 Japanese patients with essential hypertension (HT), who had been on stable antihypertensive medication for at least 3 months, and with medical data, including radial artery tonometry-derived parameters relating to CBP, from seven major centers and their related medical facilities participating in the Antihypertensives and Blood pressure of Central artery study in Japan (ABC-J). The subjects also included 1,094 participants receiving no antihypertensive therapy. From the untreated population, 848 nonhypertensive (non-HT) subjects were extracted based on BP (systolic BP (SBP) <140 mm Hg and diastolic BP (DBP) <90 mm Hg) measured when the radial artery pulse wave was recorded (**Table 1**).

The study protocol was approved by the institutional review board of each ABC-J center. Data were obtained from archived medical records of participants in whom the radial artery pulse wave had been recorded in accordance with the method described below. All participants were informed of this study procedure and gave consent to providing their data. The data were collected from January to December in 2007.

Radial artery pulse wave measurement and evaluation of CBP. Radial artery pressure pulse waveform was recorded with an automated tonometric system, HEM-9000AI (Omron Healthcare, Kyoto, Japan) in a sitting position after at least 5 min of rest. The waveform was calibrated automatically using built-in oscillometric brachial sphygmomanometry. The peak and bottom of the radial pressure wave were adjusted to brachial SBP and DBP, respectively. The HEM-9000AI algorithm automatically performed online detection of the second peak (late systolic inflection) based on the second maxima of the fourth derivative of the radial pressure waveform to determine the radial augmentation index as well as the late or second SBP (SBP2), as shown in **Figure 1**. The outline of the built-in algorithm of this device has been reported elsewhere.[15]

In order to assess CBP-lowering effects selectively, we focused on central SBP levels relative to brachial SBP because absolute CBP levels largely depend on the mean BP level, which is nearly identical for both central and peripheral sites.[16] **Figure 1** shows the parameters derived from radial pulse waveform analysis. The height of the second peak corresponds to SBP2, which is reportedly an alternative[17] to or is closely related[18] to directly measured central aortic SBP. SBP2 obtained by the same device as in this study has also been reported to be comparable to central SBP estimated using a generalized aorto-radial transfer function.[19,20] We created an index, ΔSBP2, defined as "SBP2 − SBP" (**Figure 1**), to assess peak SBP reduction between peripheral and central sites.

Therapeutic drugs. Antihypertensive drugs being administered at the time of measurement were obtained from medical records together with coadministered antidyslipidemia and antidiabetic drugs, nitrates and/or nicorandil. All class names and antihypertensive abbreviations are in the footnote of **Table 2**.

Data analysis. All data are expressed as the mean ± 1 s.d. unless otherwise specified. Intergroup comparisons of mean values and ratios of subjects' characteristics were tested by unpaired Student's *t*-test and Fisher's exact test, respectively. Multiple regression analysis (forced entry method) was employed to compare all classes of, as well as broadly grouped (vasodilating (VD) and non-VD), antihypertensive drugs in terms of the association with ΔSBP2, where VD included angiotensin receptor blockers (ARB), ACEI, CCB, and α-blocker; and non-VD included Diur and βBL. Categorical data, such as gender and drugs, were assessed as dummy variables ("0" or "1") in regression models. For VD and non-VD, we made a dummy variable, "Drug group," which was coded "1" if the patient took any one or several non-VD drugs without VD drugs in combination whereas code "0" indicated any others, including any one or several VD drugs and mixed combinations of VD plus non-VD drugs. In Model 1 in **Table 3**, where patients with mixed combination were excluded from the subject population, code "0" implied that a patient took

Table 1 | Subject characteristics

	Treated HT	Non-HT	P
N (pts)	1,727	848	
Male/female (pts)	884/843	468/380	0.059
Age (years)	66.5 ± 11.5	50.3 ± 16.7	<0.001
Height (cm)	157.6 ± 9.3	162.4 ± 9.6	<0.001
Weight (kg)	60.0 ± 11.4	59.2 ± 10.5	0.109
BMI (kg/m²)	24.0 ± 3.4	22.4 ± 2.9	<0.001
PR (bpm)	69.2 ± 12.0	69.1 ± 10.4	0.949
Calibrated radial artery tonometry			
SBP (mm Hg)	137.7 ± 17.2	118.4 ± 11.6	<0.001
SBP2 (mm Hg)	127.6 ± 18.3	106.7 ± 14.3	<0.001
DBP (mm Hg)	74.8 ± 11.8	70.0 ± 8.9	<0.001
rAI (%)	85.5 ± 14.0	76.7 ± 17.1	<0.001
Number of drugs in combination, pts (%)			
1	596 (34.5%)		
2	632 (36.6%)		
3	390 (22.6%)		
4	97 (5.6%)		
5	12 (0.7%)		

BMI, body mass index; BP, blood pressure; DBP, diastolic blood pressure; Diur, diuretics; HT, treated hypertensives; non-HT, nonhypertensives; PR, pulse rate; pts, number of patients; rAI, radial augmentation index; SBP, systolic blood pressure; SBP2, late systolic blood pressure.

any one or several VD drugs only. Multiple regression models were used for adjusted comparisons of individual classes or broadly divided groups of antihypertensive drugs and their combinations, in which determinants of ΔSBP2 other than a specified antihypertensive drug or a drug combination were adjusted. Because pulse rate is largely attributable to the drug effect itself, it was not adjusted unless otherwise specified. The adjusted comparisons were as follows:

1. A multiple regression model was constructed for ΔSBP2 forcing all possible independent variables, including all antihypertensive drugs either broadly grouped (VD vs. non-VD) or grouped by drug class, to enter the models. Interactive terms relating to drug combinations were examined and significant interactive terms were considered to be included in the model.

2. For the non-HT population, a separate model without the drug variable was constructed. Based on this model, ΔSBP2 was modified by adjusting common confounders (age, gender, height, BMI, DBP) to the mean value of HT. This provided the estimated physiological reference value of ΔSBP2 when the DBP level was comparable with treated HT.

3. We collected adjusted ΔSBP2 data for an individual group or class of antihypertensive agents by extracting cases given a specified type of drugs irrespective of monotherapy or combination. Likewise, data for each combination of two specified antihypertensive classes were collected, including combinations of ≥3 drugs.

4. In addition to adjusting for all common confounders and the use of nitrates (="0"), further adjustments of ΔSBP2 were made for each specified group or class of drugs or their combination. For interdrug group or interclass comparisons, variables for irrelevant classes coadministered and interactive terms were set as "0" (i.e., not used). Similarly, for intercombination therapy comparisons,

variables for coadministered drugs not included in the specified combination as well as interactive terms (unless applicable) were set as "0."

5. Interdrug group, interclass or intercombination therapy comparisons of CBP indexed by ΔSBP2 were made using the adjusted data, as described above. Adjusted ΔSBP2 was also compared between each drug group and non-HT. Two-group comparisons, including VD only vs. non-VD only and each drug group vs. non-HT, were tested by the Mann–Whitney U-test, whereas interclass and intercombination therapy as well as intertreatment group (i.e., VD vs. non-VD vs. Mixed) comparisons were tested by the Kruskal–Wallis test with multiple comparisons by the Games–Howell method.

All statistical analyses were performed with a commercially available statistical package (SPSS, version 11.0; SPSS, Chicago, IL) and spreadsheet calculation (Excel 2007; Microsoft, Washington, DC). P values <0.05 were regarded as significant.

RESULTS

Subjects' characteristics and details of antihypertensive therapy are shown in **Tables 1** and **2**. Overall, ≥60% patients were treated with CCB or ARB. Only one third of participants was treated with monotherapy (**Table 1**), and monotherapy with some classes of drugs was very rare (**Table 2**), which made it difficult to compare all individual antihypertensive classes directly. We therefore first examined broadly divided drug groups, i.e., VD and non-VD. As shown in **Table 3**, partial regression coefficient (B) estimates of "Drug group" in Models 1 and 2 consistently indicated that ΔSBP2 was 2.7 mm Hg higher with non-VD than with VD when all included confounders were adjusted.

In 510 participants who provided a detailed clinical data set, including laboratory data and comorbidities, none showed significant associations with ΔSBP2 by multiple regression


Figure 1 | Definitions of ΔSBP2 and radial augmentation index (rAI), and relationship between each parameter derived from calibrated tonometric radial pressure waveform (P_{Ra} = solid line; right) and corresponding putative aortic pressure waveform (P_{Ao} = dotted line; left). These definitions are expressed as formulas inside the Figure. cPP, central pulse pressure; cSBP, central systolic blood pressure; DBP, diastolic blood pressure; PP, radial pulse pressure; PP_1, ejection peak amplitude of P_{Ra}; PP_2, second peak amplitude of P_{Ra}; SBP, radial peak systolic blood pressure; SBP1, radial artery pressure at the ejection peak, which is not necessarily identical to the systolic peak of P_{Ra}; SBP2, radial artery pressure at the second peak.

Table 2 | Details of antihypertensive therapy

	Class of antihypertensives[a]						
	ARB	**ACEI**	**CCB**	**αBL**	**Diur**	**βBL**	**Nitro**
N (pts (%))	1,019 (59.0)	207 (12.0)	1,178 (68.2)	161 (9.3)	422 (24.4)	373 (21.6)	121 (7.0)
Male/female (pts)	537/482	125/82	601/577	87/74	190/232	189/184	84/37
Age (years)	66.7 ± 11.7	64.8 ± 13.2	67.4 ± 10.7	65.7 ± 10.9	66.6 ± 11.4	66.5 ± 11.0	73.3 ± 8.2
Height (cm)	157.7 ± 9.5	158.7 ± 9.7	157.1 ± 9.3	157.7 ± 8.0	157.0 ± 9.4	158.4 ± 9.0	157.5 ± 8.4
Weight (kg)	60.6 ± 11.8	60.3 ± 11.5	60.1 ± 11.5	61.9 ± 11.2	61.7 ± 11.6	61.5 ± 11.4	57.8 ± 9.2
BMI (kg/m²)	24.2 ± 3.5	23.8 ± 3.2	24.2 ± 3.4	24.8 ± 3.7	25.0 ± 3.6	24.4 ± 3.5	23.2 ± 2.7
PR (bpm)	69.1 ± 11.8	70.9 ± 13.1	69.1 ± 12.2	68.1 ± 12.9	68.2 ± 12.2	63.7 ± 11.2	69.0 ± 13.0
Calibrated radial artery tonometry							
SBP (mm Hg)	138.5 ± 17.3	137.4 ± 17.1	138.2 ± 16.9	138.9 ± 17.3	134.4 ± 18.1	134.5 ± 17.6	139.2 ± 16.4
SBP2 (mm Hg)	128.1 ± 18.7	126.3 ± 18.1	127.7 ± 18.0	126.8 ± 18.0	124.8 ± 18.1	126.2 ± 18.9	125.3 ± 18.1
DBP (mm Hg)	74.9 ± 12.0	75.0 ± 11.5	74.6 ± 11.6	73.7 ± 12.3	71.7 ± 12.6	73.2 ± 11.8	72.2 ± 10.9
rAI (%)	85.0 ± 13.9	83.8 ± 13.9	85.3 ± 14.0	83.6 ± 15.5	85.5 ± 13.1	88.2 ± 14.5	80.9 ± 14.8
Number of drugs prescribed:							
1 (pts)	235	54	274	0	26	34	16
≥2 (pts)	784	153	904	161	396	339	105
	Drug classes used in combination[b]						
	ARB+CCB	**ARB+Diur**	**ARB+βBL**	**CCB+ACEI**	**CCB+Diur**	**CCB+βBL**	**Diur+βBL**
N (pts (%))	633 (36.7)	274 (15.9)	201 (11.6)	120 (6.9)	267 (15.5)	257 (14.9)	116 (6.7)
Male/female (pts)	345/288	123/151	106/95	72/48	122/145	127/130	54/62
Age (years)	67.7 ± 11.4	67.6 ± 11.0	67.1 ± 11.5	67.2 ± 10.8	67.6 ± 10.7	66.4 ± 11.2	65.9 ± 11.4
Height (cm)	157.4 ± 9.6	156.5 ± 9.5	158.2 ± 9.3	157.5 ± 9.9	156.3 ± 9.1	158.2 ± 9.2	158.2 ± 9.3
Weight (kg)	61.0 ± 12.2	61.7 ± 12.0	62.4 ± 12.4	60.2 ± 11.7	61.4 ± 11.1	62.0 ± 11.3	64.5 ± 11.9
BMI (kg/m²)	24.5 ± 3.6	25.1 ± 3.7	24.8 ± 3.9	24.1 ± 3.3	25.1 ± 3.6	24.7 ± 3.4	25.7 ± 3.9
PR (bpm)	69.0 ± 12.1	68.2 ± 12.1	63.0 ± 11.0	71.9 ± 13.9	67.4 ± 11.9	63.4 ± 11.1	62.8 ± 10.7
Calibrated radial artery tonometry							
SBP (mm Hg)	139.3 ± 17.1	135.1 ± 18.3	135.6 ± 18.2	140.1 ± 15.3	135.2 ± 17.8	134.8 ± 16.9	130.3 ± 18.7
SBP2 (mm Hg)	128.2 ± 18.7	125.2 ± 18.1	127.1 ± 20.0	128.1 ± 16.0	125.1 ± 17.2	126.1 ± 18.5	122.4 ± 19.4
DBP (mm Hg)	74.2 ± 12.0	71.7 ± 12.4	72.8 ± 12.6	75.4 ± 11.1	72.0 ± 11.8	72.8 ± 11.7	70.8 ± 12.1
rAI (%)	84.6 ± 14.4	85.2 ± 13.1	88.1 ± 14.0	83.6 ± 13.6	85.3 ± 12.4	87.5 ± 14.0	87.5 ± 14.3
Number of drugs prescribed							
2 (pts)	309	66	28	62	40	67	2
≥3 (pts)	324	208	173	58	227	190	114

ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blockers; DBP, diastolic blood pressure; Diur, diuretics; Nitro, nitrates or nicorandil; pts, number of patients; αBL, α-blockers; βBL, β-blockers.
[a]Because of its vasoactive action, Nitro is included although drugs in this class are not classified as antihypertensives. [b]The number for each specified drug combination includes patients taking three or more antihypertensive other than the specified drugs.

analysis (**Supplementary Table S1a** online). We further examined the multiple regression models individually, including each clinical variable available in this study. Although the total cholesterol level ($N = 784$; $B = 0.02$ mm Hg·dl/mg; $P = 0.01$), serum creatinine ($N = 1,374$; $B = -0.27$ mm Hg·dl/mg; $P = 0.04$), and hemoglobin ($N = 868$; $B = 0.27$ mm Hg·dl/g; $P = 0.03$) reached a significant level, only modest influences on the B estimates of "Drug group" were observed (**Supplementary Table S1b** online).

ΔSBP2 data adjusted using Model 1 were compared between VD only and non-VD only as well as with non-HT, in which

adjusted ΔSBP2 was estimated based on Model 3 (area A in **Figure 2**). Although the difference between VD and non-VD was evident, N with actual non-VD only was far fewer than with VD only, which resulted in larger variance in this group. We then estimated ΔSBP2 with VD only or non-VD only in patients with mixed combination therapy based on Model 2, which increased the number of data compared. The results are shown with adjusted data of actual mixed combination within area B in **Figure 2**. Estimated ΔSBP2 with VD alone (-10.1 mm Hg) was lower than with non-VD alone (-6.6 mm Hg), and even lower than in non-HT (-7.7 mm Hg).

Table 3 | Multiple regression models of ΔSBP2 in specified populations

Independent variables	Model 1				Model 2				Model 3			
N	1,094				1,711				848			
Adjust R^2	0.366				0.366				0.553			
	B	95% CI	β	P	B	95% CI	β	P	B	95% CI	β	P
Physical variables												
Gender	−2.808	−3.963 to −1.654	−0.170	<0.001	−2.687	−3.571 to −1.803	−0.169	<0.001	−4.539	−5.645 to −3.432	−0.292	<0.001
Age	−0.002	−0.040 to 0.036	−0.003	0.921	−0.005	−0.035 to 0.026	−0.007	0.764	0.176	0.151 to 0.201	0.378	<0.001
Height	−0.186	−0.251 to −0.120	−0.212	<0.001	−0.170	−0.221 to −0.119	−0.199	<0.001	−0.119	−0.181 to −0.057	−0.147	<0.001
BMI	−0.293	−0.410 to −0.175	−0.120	<0.001	−0.210	−0.301 to −0.120	−0.090	<0.001	−0.469	−0.598 to −0.340	−0.174	<0.001
Hemodynamic variables												
PR	−0.342	−0.375 to −0.308	−0.492	<0.001	−0.336	−0.362 to −0.310	−0.508	<0.001	−0.238	−0.273 to −0.203	−0.318	<0.001
DBP	0.149	0.114 to 0.184	0.212	<0.001	0.141	0.114 to 0.168	0.210	<0.001	0.257	0.214 to 0.300	0.295	<0.001
Group of drugs												
Nitro	−3.393	−5.058 to −1.728	−0.098	<0.001	−3.631	−4.913 to −2.350	−0.109	<0.001				
Drug group	2.678	0.984 to 4.372	0.075	0.002	2.709	1.073 to 4.345	0.064	0.001				
Mixed					0.448	−0.209 to 1.105	0.027	0.181				

Drug group: code "1" = treated with non-VD only; code "0" = other treatments with VD only and mixed combination with VD and non-VD. Mixed: code "1" = mixed combination with VD and non-VD; code "0" = all other treatments (with VD only or non-VD only). VD (vasodilating antihypertensive drugs) includes angiotensin receptor blockers, angiotensin-converting enzyme inhibitors, calcium channel blockers, and α-blockers; non-VD (nonvasodilating antihypertensive drugs) includes diuretics and β-blockers. Subject populations for Models 1 through 3 were hypertensives (HT) without mixed (VD + non-VD) combination, HT including mixed combination except Nitro only and non-HT, respectively. Sixteen HT patients taking Nitro alone were excluded from Models 1 and 2. ΔSBP2 is defined in **Figure 1**. 95% CI, 95% confidence interval of B; B, nonstandardized partial regression coefficient; BMI, body mass index; DBP, diastolic blood pressure; PR, pulse rate; β, standardized partial regression coefficient.

In contrast, with non-VD alone, it was even higher than in non-HT.

To enable the characterization of each individual class, we constructed a model including all classes of antihypertensive agents and a significant interactive term as independent variables (Table 4). Only "CCB × Diur" was significant among all interactive terms that could have been assessed previously (Supplementary Table S2a–d online). Among antihypertensive classes, ARB, CCB, and α-blockers had significant associations with ΔSBP2.

Using this model, we performed adjusted interclass comparisons of antihypertensive drugs to characterize each individual class in terms of ΔSBP2 (Figure 3a). Treatments with VD antihypertensive classes showed a lower ΔSBP2 than nonvasodilators comparably to VD and non-VD in Figure 2. Most importantly, no significant difference in ΔSBP2 was detected among any VD classes. The mean level of ΔSBP2 (−9.7 mm Hg) was 3.3 and 2.0 mm Hg lower than with nonvasodilators and in non-HT. In contrast, with βBL or diuretics, the averaged ΔSBP2 value was 1.3 mm Hg higher than in non-HT. When pulse rate adjustment was added (Figure 3b), the higher level of ΔSBP2 associated with

βBL was reduced, which abolished the significant difference from ACEI.

Adjusted comparisons of ΔSBP2 among treatments with frequently used combinations of antihypertensives were also performed (Figure 4) based on the model (Table 4). The combination of two different VD antihypertensive classes, such as CCB plus ARB or ACEI, showed the lowest level of ΔSBP2 (−10.5 mm Hg; Figure 4a), which was lower than in any single VD antihypertensive class shown in Figure 3a. When the drug combined with ARB or CCB was a diuretic or βBL, the ΔSBP2 value increased in this order. The combination of diuretics and βBL showed the highest ΔSBP2 (−3.9 mm Hg). Additional pulse rate adjustment tended to reduce ΔSBP2 with βBL-including combinations, whereas its influence varied for Diur-including combinations. Differences between the combination of CCB plus ARB or ACEI and that of diuretics plus βBL remained significant even after pulse rate adjustment.

DISCUSSION

In the present study, all individual classes of antihypertensive agents commonly used in Japan and combinations of two different classes were tentatively characterized in terms of central

Table 4 | Multiple regression models of ΔSBP2 in treated hypertensives

N		1,727		
Adjusted R^2		0.379		
Independent variables	B	95% C.I.	β	P
Physical variables				
Gender	−2.358	−3.236 to −1.480	−0.148	<0.001
Age	−0.004	−0.034 to 0.027	−0.005	0.813
Height	−0.185	−0.235 to −0.134	−0.215	<0.001
BMI	−0.200	−0.290 to −0.109	−0.085	<0.001
Hemodynamic variables				
PR	−0.336	−0.362 to −0.310	−0.508	<0.001
DBP	0.140	0.113 to 0.167	0.207	<0.001
Class of drugs				
ARB	−1.012	−1.682 to −0.343	−0.062	0.003
ACEI	−0.516	−1.512 to 0.479	−0.021	0.309
CCB	−0.837	−1.619 to −0.056	−0.049	0.036
αBL	−2.122	−3.158 to −1.087	−0.077	<0.001
Diur	1.890	0.690 to 3.090	0.102	0.002
βBL	0.537	−0.218 to 1.292	0.028	0.163
Nitro	−3.675	−4.882 to −2.468	−0.118	<0.001
Interactive term				
CCB × Diur	−1.953	−3.414 to −0.493	−0.089	0.009

ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; BMI, body mass index; CCB, calcium channel blockers; DBP, diastolic blood pressure; Diur, diuretics; Nitro, nitrates or nicorandil; PR, pulse rate; αBL, α-blockers; βBL, β-blockers.

Figure 2 | Adjusted comparisons of ΔSBP2 between vasodilating (VD) and non-VD antihypertensive drugs. VD group includes angiotensin receptor blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, α-blockers, and non-VD group includes β-blockers and diuretics. Data are shown as the mean level (horizontal line) and the 95% confidence interval (box height) as well as the range of ±1 s.d. by a vertical error bar. P value in the lower part of the figure indicates the result of the Mann–Whitney U-test of each specified intergroup comparison unless specified in the figure (K-W, Kruskal–Wallis test; G-H, Games–Howell multiple comparison test). The number in each box indicates the difference (mm Hg) of mean ΔSBP2 between compared groups. Gray area A shows the comparison between actual mean ΔSBP2 and non-VD only regimens irrespective of the number of drugs. ΔSBP2 data were adjusted for confounding factors (age, gender, height, BMI, DBP, and the use of nitrates = "0") based on Model 1 in **Table 3**. Cases with mixed combination (VD + non-VD) regimens were excluded. Gray area B shows the comparison among VD(est), non-VD(est) and Mixed combinations of VD and non-VD. "(est)" indicates the result estimated from mixed combination, for which the effects of VD or non-VD alone on ΔSBP2 were estimated using Model 2 in **Table 3**. Data in the nonhypertensive (non-HT) population indicate the physiological reference value of ΔSBP2 estimated by adjusting confounding factors to the mean value of treated HT using Model 3 in **Table 3**.

effects indexed by ΔSBP2. We found that treatment with any VD antihypertensive class showed lower CBP than any nonvasodilatory class when peripheral BP was lowered to the same level. CBP assessment was highly objective using a validated semiautomatic radial artery tonometry system,[15,19] which could minimize variance and errors related to observer or operator skill.

Feature of ΔSBP2 and its cross-sectional determinants
The augmentation index reportedly depends on age,[21] gender,[22] height,[23] heart rate,[24,25] and BP levels.[26] ΔSBP2 relates to radial augmentation index by definition as radial augmentation index is the ratio of (PP+ΔSBP2) to PP1 (**Figure 1**). The ΔSBP2 value is always negative and reflects the actual reduction in SBP and pulse pressure from peripheral to central sites. Comparing Models 2 and 3 (**Table 3**), significant associations between these variables and ΔSBP2 observed in the non-HT population were partially preserved even in treated HT except for age.

Interpretation of the results
In addition to adjustment for common confounders, model-based estimation of ΔSBP2 compensating for coadministered drug effects enabled interclass comparisons of central

effects of antihypertensives that were impossible to make directly with raw data, and played a "data-mining" role in this study.

Central effects of antihypertensive classes. The lower level of CBP, even lower than in non-HT, with VD antihypertensives administered alone (area B in **Figures 2** and **3a**) might lead to more effective unloading of pulsatile mechanical stress on the cardiovascular system than nonvasodilatory agents. The observed reduction of ΔSBP2 with βBL by additional pulse rate adjustment (**Figure 3b**) suggested that the CBP-raising feature of βBL might be attributable to its negative chronotropic effect.

ORIGINAL CONTRIBUTIONS

Figure 3 | Adjusted interclass comparisons of ΔSBP2. Data are shown in the same format as in **Figure 2**. A solid or striped horizontal bar in the lower part of the figure denotes a comparison with significant difference determined by Games–Howell multiple comparison test indicating P <0.001 or P < 0.05, respectively. The number of patients included in each antihypertensive group is shown in **Table 2** ("Class of antihypertensives"). As indicated in that table, it includes patients treated with two or more drugs in combination as well as patients actually taking the specified drug alone. (a) Using the model shown in **Table 4**, ΔSBP2 was adjusted for age, gender, height, BMI, DBP, coadministered drugs (including Nitro = "0") other than the specified antihypertensive class, and the interactive term. (b) In addition to the adjustment in **Figure 3a**, ΔSBP2 values were adjusted for pulse rate. ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blockers; Diur, diuretics; αBL, α-blockers; βBL, β-blockers.

Figure 4 | Adjusted comparisons of ΔSBP2 among frequently used combinations of antihypertensive agents. The number of cases included in each treatment group is indicated in **Table 2** ("Drug classes used in combination"). As indicated in that table, it includes patients treated with three or more drugs as well as patients actually taking only two specified drugs in combination. The format of each graph is as in **Figure 3**. (a) Using the model shown in **Table 4**, data were adjusted for age, gender, height, BMI, DBP, and coadministered drugs (including Nitro = "0") other than the specified two-drug combination if applicable. The interactive term was set as "0" except for the CCB+Diur combination. (b) In addition to the adjustment in **Figure 4a**, data were also adjusted for pulse rate. ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blockers; Diur, diuretics; βBL, β- blockers.

Central effects of major combinations of antihypertensive drugs. **Figure 4a** suggested some additive CBP-lowering effects of two different vasodilatory classes. In contrast, along with higher ΔSBP2 above the physiological level with non-VD (**Figure 2**), the findings with non-VD-including combinations suggested that the central effects of non-VD antihypertensives were CBP-raising rather than less potent CBP-lowering.

The negative *B* estimate of the significant interactive term, "CCB × Diur", suggested some synergistic CBP-lowering effect.

Comparison with other studies

The results of this study are consistent with reported studies, such as the CAFE study,[1] and other small-scale studies.[3–11] More recently, other small-scale treatment trials dealing with the effects on CBP of a newer class of antihypertensives, ARB, compared with βBL, have been reported.[27–29] The results of these studies can be summarized as the superiority of vasodilatory antihypertensives, including CCB, ARB, and ACEI, to nonvasodilatory agents, such as diuretics and βBL. Similar to the CAFE study, the higher CBP level with βBL-including treatments was evident in this study; however, these studies used only limited antihypertensive regimens. This cross-sectional observation, including a data-mining model-based estimation process, enabled tentative but simultaneous comparisons of all commonly used antihypertensive agents

specifically in terms of central effects by individual class as well as by common combination regimens. Additionally, this study reported ΔSBP2 levels in HT compared with an adjusted physiological reference level.

Limitations

Issues relating to the observational study design. This study was designed as an exploratory study to generate rather than to test hypotheses; therefore, the results cannot confirm the causal effects of each drug class on CBP but provide hypotheses to be assessed. Because of the cross-sectional and observational design, in which the selection of antihypertensive drugs was left to the clinician, and might have been related to patients' clinical characteristics, an indication bias was inevitable. Although we examined available clinical variables in some participants (**Supplementary Tables S1a and S1b** online), they included only some of the population studied and all data could not be adjusted for clinical confounders. The influence of indication bias could therefore not be avoided and should be taken into consideration when interpreting the results of this study.

Issues relating to model-based adjustment. In addition, the results should be interpreted with caution for the following reasons. Data adjustments were based on linear regression models. The influences of adjusted variables are not necessarily linear. Also, the doses and duration of specified antihypertensive medications were not taken into consideration due

to the limited study design. Although the findings obtained from such analysis are not conclusive, we believe that they can provide information to develop hypotheses.

Interpretation of nitrates. As nitrates are not classified as antihypertensive agents, data were compared adjusting for the use of this type of drugs. Only a minority of subjects was given nitrates (**Table 2**), but significantly lower ΔSBP2 was observed. This may be attributable to, at least in part, cardiac dysfunction,[30,31] because nitrates are usually prescribed for cardiac patients. We could not adjust for cardiac function because of the absence of required information. It is well-known that nitrates markedly reduce aortic wave reflections or late systolic BP augmentation.[4,32,33] In this study, to compare each class of antihypertensives in terms of central effects, the DBP level was adjusted, indicating that the mean pressure-lowering effect was ignored, which was likely to exaggerate the effect of nitrates as a central antihypertensive. Although a small-scale uncontrolled trial using extended-release isosorbide mononitrate has already been reported,[7] randomized intervention trials are necessary to elucidate whether significant associations with lower ΔSBP2 are from pharmacological effects or cardiac dysfunction, as well as its clinical benefit for HT without cardiac dysfunction.

In summary, among all classes of antihypertensive drugs, any single VD antihypertensive agent (CCB, ARB, ACEI, or α-blockers) might lower CBP without interclass difference, whereas nonvasodilators (Diur and βBL) might raise CBP above the physiological level when peripheral BP is adjusted to the same level. The other novel findings obtained in this study are that (i) among assessable combinations, only CCB+Diur showed synergistic interaction; (ii) otherwise, coadministered VD antihypertensives did not affect the CBP-raising features of nonvasodilators; (iii) the CBP-raising effect of βBL is chiefly attributable to negative chronotropism; and (iv) total cholesterol level, serum creatinine, and hemoglobin showed modest but significant associations with ΔSBP2.

Finally, the hypothetical feature of each antihypertensive class in terms of CBP and its prognostic predictive value should be assessed by large-scale randomized intervention trials.

1. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. *Circulation* 2006; 113:1213–1225.

2. Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T, Umans JG, Howard BV. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. *Hypertension* 2007; 50:197–203.

3. Guerin AP, Pannier BM, Marchais SJ, Metivier F, Safar M, London GM. Effects of antihypertensive agents on carotid pulse contour in humans. *J Hum Hypertens* 1992; 6 Suppl 2:S37–S40.

4. Takazawa K, Tanaka N, Takeda K, Kurosu F, Ibukiyama C. Underestimation of vasodilator effects of nitroglycerin by upper limb blood pressure. *Hypertension* 1995; 26:520–523.

5. Cholley BP, Shroff SG, Sandelski J, Korcarz C, Balasia BA, Jain S, Berger DS, Murphy MB, Marcus RH, Lang RM. Differential effects of chronic oral antihypertensive therapies on systemic arterial circulation and ventricular energetics in African-American patients. *Circulation* 1995; 91:1052–1062.

6. Chen CH, Ting CT, Lin SJ, Hsu TL, Yin FC, Siu CO, Chou P, Wang SP, Chang MS. Different effects of fosinopril and atenolol on wave reflections in hypertensive patients. *Hypertension* 1995; 25:1034–1041.

7. Stokes GS, Ryan M. Can Extended-Release Isosorbide Mononitrate be Used as Adjunctive Therapy for Systolic Hypertension? An Open Study Employing Pulse-Wave Analysis to Determine Effects of Antihypertensive Therapy. *Am J Geriatr Cardiol* 1997; 6:11–19.

8. Pannier BM, Guerin AP, Marchais SJ, London GM. Different aortic reflection wave responses following long-term angiotensin-converting enzyme inhibition and beta-blocker in essential hypertension. *Clin Exp Pharmacol Physiol* 2001; 28:1074–1077.

9. Asmar R, Gosse P, Topouchian J, N'tela G, Dudley A, Shepherd GL. Effects of telmisartan on arterial stiffness in Type 2 diabetes patients with essential hypertension. *J Renin Angiotensin Aldosterone Syst* 2002; 3:176–180.

10. de Luca N, Asmar RG, London GM, O'Rourke MF, Safar ME; REASON Project Investigators. Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects. *J Hypertens* 2004; 22:1623–1630.

11. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. *Am J Hypertens* 2004; 17:118–123.

12. O'Rourke M. Systolic blood pressure: arterial compliance and early wave reflection, and their modification by antihypertensive therapy. *J Hum Hypertens* 1989; 3 Suppl 1:47–52.

13. O'Rourke MF. Arterial mechanics and wave reflection with antihypertensive therapy. *J Hypertens Suppl* 1992; 10:S43–S49.

14. Ting CT, Chen CH, Chang MS, Yin FC. Short- and long-term effects of antihypertensive drugs on arterial reflections, compliance, and impedance. *Hypertension* 1995; 26:524–530.

15. Melenovsky V, Borlaug BA, Fetics B, Kessler K, Shively L, Kass DA. Estimation of central pressure augmentation using automated radial artery tonometry. *J Hypertens* 2007; 25:1403–1409.

16. Pauca AL, Wallenhaupt SL, Kon ND, Tucker WY. Does radial artery pressure accurately reflect aortic pressure? *Chest* 1992; 102:1193–1198.

17. Pauca AL, Kon ND, O'Rourke MF. The second peak of the radial artery pressure wave represents aortic systolic pressure in hypertensive and elderly patients. *Br J Anaesth* 2004; 92:651–657.

18. Takazawa K, Kobayashi H, Shindo N, Tanaka N, Yamashina A. Relationship between radial and central arterial pulse wave and evaluation of central aortic pressure using the radial arterial pulse wave. *Hypertens Res* 2007; 30:219–228.

19. Richardson CJ, Maki-Petaja KM, McDonnell BJ, Hickson SS, Wilkinson IB, McEniery CM. Comparison of estimates of central systolic blood pressure and peripheral augmentation index obtained from the Omron HEM-9000AI and SphygmoCor systems. *Artery Research* 2009; 3:24–31.

20. Hickson SS, Butlin M, Mir FA, Graggaber J, Cheriyan J, Khan F, Grace AA, Yasmin, Cockcroft JR, Wilkinson IB, McEniery CM; Anglo-Cardiff Collaboration Trial Investigators. The accuracy of central SBP determined from the second systolic peak of the peripheral pressure waveform. *J Hypertens* 2009; 27:1784–1788.

21. Kelly R, Hayward C, Avolio A, O'Rourke M. Noninvasive determination of age-related changes in the human arterial pulse. *Circulation* 1989; 80:1652–1659.

22. Gatzka CD, Kingwell BA, Cameron JD, Berry KL, Liang YL, Dewar EM, Reid CM, Jennings GL, Dart AM. Gender differences in the timing of arterial wave reflection beyond differences in body height. *J Hypertens* 2001; 19:2197–2203.

23. London GM, Guerin AP, Pannier BM, Marchais SJ, Metivier F. Body height as a determinant of carotid pulse contour in humans. *J Hypertens Suppl* 1992; 10:S93–S95.

24. Wilkinson IB, MacCallum H, Flint L, Cockcroft JR, Newby DE, Webb DJ. The influence of heart rate on augmentation index and central arterial pressure in humans. *J Physiol (Lond)* 2000; 525 Pt 1:263–270.

25. Wilkinson IB, Mohammad NH, Tyrrell S, Hall IR, Webb DJ, Paul VE, Levy T, Cockcroft JR. Heart rate dependency of pulse pressure amplification and arterial stiffness. *Am J Hypertens* 2002; 15:24–30.

26. Nürnberger J, Dammer S, Opazo Saez A, Philipp T, Schäfers RF. Diastolic blood pressure is an important determinant of augmentation index and pulse wave velocity in young, healthy males. *J Hum Hypertens* 2003; 17:153–158.

27. Dhakam Z, McEniery CM, Yasmin, Cockcroft JR, Brown MJ, Wilkinson IB. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. *Am J Hypertens* 2006; 19:214–219.

28. Schneider MP, Delles C, Klingbeil AU, Ludwig M, Kolloch RE, Krekler M, Stumpe KO, Schmieder RE. Effect of angiotensin receptor blockade on central haemodynamics in essential hypertension: results of a randomised trial. *J Renin Angiotensin Aldosterone Syst* 2008; 9:49–56.

29. Vyssoulis GP, Karpanou EA, Kyvelou SM, Adamopoulos DN, Antonakoudis GC, Deligeorgis AD, Cokkinos DV, Stefanadis CI. Beneficial effect of angiotensin II type 1 receptor blocker antihypertensive treatment on arterial stiffness: the role of smoking. *J Clin Hypertens (Greenwich)* 2008; 10:201–207.

30. Westerhof N, O'Rourke MF. Haemodynamic basis for the development of left ventricular failure in systolic hypertension and for its logical therapy. *J Hypertens* 1995; 13:943–952.

31. Nichols WW, O'Rourke MF. *McDonald's Blood Flow in Arteries*, 5th edn. Hodders Arnold: London, 2005.

32. Yaginuma T, Avolio A, O'Rourke M, Nichols W, Morgan JJ, Roy P, Baron D, Branson J, Feneley M. Effect of glyceryl trinitrate on peripheral arteries alters left ventricular hydraulic load in man. *Cardiovasc Res* 1986; 20:153–160.

33. Fitchett DH, Simkus GJ, Beaudry JP, Marpole DG. Reflected pressure waves in the ascending aorta: effect of glyceryl trinitrate. *Cardiovasc Res* 1988; 22: 494–500.

Sympathoinhibition Induced by Centrally Administered Atorvastatin Is Associated With Alteration of NAD(P)H and Mn Superoxide Dismutase Activity in Rostral Ventrolateral Medulla of Stroke-Prone Spontaneously Hypertensive Rats

Takuya Kishi, MD, PhD, Yoshitaka Hirooka, MD, PhD, Satomi Konno, MD, and Kenji Sunagawa, MD, PhD

Abstract: Oxidative stress in the rostral ventrolateral medulla (RVLM) increases sympathetic nervous system activity (SNA). Oral treatment with atorvastatin decreases SNA through antioxidant effects in the RVLM of stroke-prone spontaneously hypertensive rats (SHRSP). We aimed to examine whether centrally administered atorvastain reduces SNA in SHRSP and, if so, to determine whether it is associated with the reduction of oxidative stress induced by alteration of activities of nicotinamide adenine dinucleotide phosphate [NAD(P)H] oxidase and superoxide dismutase (SOD) in the RVLM of SHRSP. SHRSP received atorvastatin (S-ATOR) or vehicle (S-VEH) by continuous intracerebroventricular infusion for 14 days. Mean blood pressure, heart rate, and SNA were significantly lower in S-ATOR than in S-VEH. Oxidative stress, Rac1 activity, NAD(P)H oxidase activity, Rac1, gp91^{phox} and p22^{phox} expression in the membrane fraction, and p47^{phox} and p40^{phox} expression in the cytosolic fraction in the RVLM were significantly lower in S-ATOR than in S-VEH. Rac1 expression in the cytosolic fraction and Mn-SOD activity, however, were significantly higher in S-ATOR than in S-VEH. Our findings suggest that centrally administered atorvastatin decreases SNA and is associated with decreasing NAD(P)H oxidase activity and upregulation of Mn-SOD activity in the RVLM of SHRSP, leading to suppressing oxidative stress.

Key Words: hypertension, sympathetic nerve activity, atorvastatin, oxidative stress, brain

(J Cardiovasc Pharmacol™ 2010;55:184–190)

INTRODUCTION

In the brainstem, the rostral ventrolateral medulla (RVLM) is known as one of the vasomotor centers that regulates sympathetic nervous system activity (SNA).[1,2] Previously, we reported that the levels of reactive oxygen species (ROS) in the RVLM are increased in stroke-prone spontaneously hypertensive rats (SHRSP), which is a hypertensive rat model exhibiting increased SNA. We also demonstrated that the increase in SNA was due to ROS activation,[3] consistent with the findings of other studies.[4–6] Furthermore, oral administration of atorvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, suppresses SNA probably through the inhibition of ROS in the RVLM of SHRSP.[7] Other studies suggest that central infusion of simvastatin suppresses SNA in heart failure models.[8–10] Our previous study was based on the oral administration of atorvastatin, however, and it is not known whether atorvastatin directly and chronically administered into the brain reduces the central sympathetic outflow via its effects on oxidative stress in the brain, particularly in the RVLM of hypertensive models.

In the brain, ROS are produced mainly through the activation of nicotinamide adenine dinucleotide phosphate [NAD(P)H] oxidase by the small G protein Rac1.[11,12] NAD(P)H oxidase is a multicomponent enzyme complex that comprises a membrane-bound heterodimer of gp91^{phox} (phagocytic oxidase) and p22^{phox}, and the cytosolic regulatory subunits p40^{phox}, p47^{phox}, p67^{phox}, and Rac1.[13–15] Transfection of dominant-negative Rac1 in the nucleus tractus solitarius decreases ROS and SNA.[12] Atorvastatin is also suggested to inhibit NAD(P)H oxidase activity in the vasculature,[16] the quadriceps muscle of diabetic rats,[17] and cardiomyocytes.[18] Furthermore, atorvastatin inhibits membrane translocation of Rac1, which is required for the activation of NAD(P)H oxidase in the vasculature.[16] In the kidney, rosuvastatin attenuates NAD(P)H oxidase activity through the inhibition of Rac1 and p22^{phox}.[18,19] In the brain, however, the contribution of atorvastatin to reducing ROS and its involvement in the inhibition of the membrane translocation of Rac1 and NAD(P)H oxidase activity is unknown. We previously demonstrated that Mn superoxide dismutase (SOD) activity is decreased in the RVLM of SHRSP, and the decrease contributes to the increase

in ROS.[3] A number of reports suggest that statins upregulate SOD in the vasculature.[20–23] Furthermore, the upregulation of Rac1 and NAD(P)H oxidase and the inhibition of SOD in the RVLM and nucleus tractus solitarius have major roles in increasing SNA and blood pressure (BP).[3,24] However, the mechanisms involved by which atorvastatin reduces ROS in the RVLM of SHRSP are not evaluated. The aim of the present study was thus to determine whether the sympathoinhibitory effect of atorvastatin due to the reduction of ROS in the RVLM is caused by the inhibition of Rac1-NAD(P)H oxidase activity and upregulation of Mn-SOD and Cu/Zn-SOD in the RVLM of SHRSP. Therefore, the aim of the present study was to examine the effects of atorvastatin administered into the brain and evaluate the changes in BP and SNA in SHRSP and to evaluate the oxidative stress and the NAD(P)H oxidase activity in the RVLM as the ROS generation. For this purpose, we determined the expression of Rac1, gp91[phox], and p22[phox] in the membrane fraction and the expression of Rac1 and p40[phox] in the cytosolic fraction of the RVLM. In addition, the activity of Cu/Zn-SOD, and Mn-SOD as scavenging enzymes of ROS was measured in the RVLM of intracerebroventricular (ICV) atorvastatin–treated and vehicle-infused SHRSP and Wistar Kyoto (WKY) rats.

MATERIALS AND METHODS

Animals and General Procedures

Male SHRSP/Izm rats and age-matched WKY rats (14–16 weeks old) were obtained from SLC Japan, Hamamatsu, Japan. Rats were fed a standard diet, and each strain was divided into 4 groups (SHRSP treated with atorvastatin, S-ATOR; SHRSP treated with vehicle, S-VEH; WKY treated with atorvastatin, W-ATOR; and WKY treated with vehicle, W-VEH; n = 5 per group). Atorvastatin (Pfizer, Inc, New York, NY) was dissolved in dimethyl sulfoxide and further diluted in artificial cerebrospinal fluid for a final concentration of 40 μg/mL. Atorvastatin or dimethyl sulfoxide and artificial cerebrospinal fluid was infused at 1 μL/h for 14 days with an osmotic minipump (Alzet 1003D; Alza Scientific Products, Palo Alto, CA) into the left lateral ventricle of the brain (from bregma: anteroposterior, −0.8 mm; lateral, 1.5 mm; and depth, 3.5 mm). The flow rate of agents in ICV methods was determined to have the significant effect on brainstem.[25] In a preliminary experiment, this dose of atorvastatin did not affect BP and heart rate (HR) when administered intravenously. Food and tap water were available ad libitum throughout the study. BP and HR were measured using the UA-10 radio-telemetry system (Data Science International, Dallas, TX) as described previously.[3,26–28] Urinary norepinephrine excretion (uNE) for 24 hours was calculated as an indicator of SNA, as described previously.[3,25–27] In addition, spectral analysis was performed using an adaptive autoregressive model to provide power spectra for systolic BP (SBP). Low frequency power of SBP was computed by integrating the spectra between 0.04 and 0.15 Hz, and SNA is presented as the normalized unit of the low frequency component of SBP (LFnuSBP).[29–31] Baroreflex sensitivity (BRS) was measured using the spontaneous sequence method as a parameter of autonomic control. Sequence analysis was performed to detect sequences of

3 or more beats in which there was either an increase in SBP and pulse interval (up sequence) or a decrease in SBP and pulse interval (down sequence). BRS was estimated as the mean slope of the up and down sequences.[32–34] The RVLM was defined according to a rat brain atlas as described previously.[3,26–28] The study protocol was reviewed and approved by the Committee on the Ethics of Animal Experiments at the Kyushu University Graduate School of Medical Sciences and conducted according to the Guidelines for Animal Experiments of Kyushu University.

Measurement of TBARS

The RVLM tissues were homogenized, and thiobarbituric acid (0.3%) was added to the homogenate. The mixture was extracted with a mixture of distilled water and n-butanolpyridine (15:1) and centrifuged at 1600g for 10 minutes. The amount of thiobarbituric acid reactive substances (TBARS) was determined by absorbance measured at 532 nm, as described previously.[3,7]

Expression of Rac1, gp91[phox], and p22[phox] in the Membrane Fraction and Rac1, p47[phox] and p40[phox] in the Cytosolic Fraction

Western blot analysis was used to determine the expression of Rac1 (Upstate Biotechnology, Lake Placid, NY),[12] gp91[phox], and p22[phox] in the membrane fraction (Santa Cruz Biotechnology, Santa Cruz, CA), and the expression of Rac1, p47[phox], and p40[phox] in the cytosolic fraction (Santa Cruz Biotechnology, Santa Cruz, CA) of the RVLM.

Activity of Rac1 in the RVLM

Rac1 activity can be monitored by its interaction with p21-activated kinase, which only occurs when Rac1 is active. We used a Rac1 Activation kit (Upstate Biotechnology, Lake Placid, NY) to evaluate Rac1 activity in the RVLM, as previously described.[12]

NAD(P)H Oxidase Activity

NAD(P)H-dependent superoxide production in the RVLM was measured using a lucigenin luminescence assay as described previously.[35,36] Quantification of NAD(P)H oxidase activity was expressed relative to that in WKY rats, which was assigned a value of 1.

Cu/Zn-SOD and Mn-SOD Activity in the RVLM

Cu/Zn-SOD or Mn-SOD activity was assayed by monitoring the inhibition of the rate of xanthine-mediated/ xanthine oxidase–mediated reduction of cytochrome c (pH 7.4). To discriminate between Cu/Zn-SOD and Mn-SOD activities, the assay was also performed after incubation in the presence of KCN, which selectively inhibits the Cu/Zn-SOD isoform.[37] Cu/Zn- and Mn-SOD activities were expressed relative to those in vehicle-treated WKY rats, which was assigned a value of 1.

Microinjection of Apocynin Into the Bilateral RVLM

In other S-ATOR and S-VEH, (n = 5 for each) on day 14, the NAD(P)H oxidase inhibitor apocynin (1 nmol) was microinjected bilaterally into the RVLM, as described previously.[3]

Statistical Analysis

Normally distributed variables were expressed as mean ± SD. An unpaired *t* test was used to compare the differences between groups of normally distributed variables, and the Mann–Whitney *U* test was used to compare differences between groups of non–normally distributed variables. A 2-factor repeated-measures analysis of variance was used to compare differences between groups. Differences were considered to be statistically significant with a *P* value of less than 0.05.

RESULTS

BP, HR, SNA, and BRS

Mean BP (MBP) and HR were significantly decreased on day 4 after the administration of atorvastatin in S-ATOR. On day 14, MBP, HR, 24-hour uNE, and LFnuSBP were significantly higher in S-VEH than in W-VEH and lower in S-ATOR than in S-VEH (Fig. 1A–D). BRS was significantly lower in S-VEH than in W-VEH (12.8 ± 2.3 vs. 19.7 ± 1.8 ms/mm Hg, n = 5 for each; *P* < 0.05) and significantly higher in S-ATOR than in S-VEH (16.4 ± 1.6 vs. 12.8 ± 2.3 ms/mm Hg, n = 5 for each; *P* < 0.05). Mean BP, HR, 24-hour uNE, LFnuSBP, and BRS values did not significantly differ between W-ATOR and W-VEH (Fig. 1A–D).

Oxidative Stress Measured by TBARS Methods in the RVLM

Oxidative stress in the RVLM measured by the TBARS method was significantly lower in S-ATOR than in S-VEH (Fig. 2). Oxidative stress did not differ significantly between W-ATOR and W-VEH (Fig. 2).

Activity of NAD(P)H Oxidase and Rac1 in the RVLM

The activity of NAD(P)H oxidase was significantly lower in S-ATOR than in S-VEH (Fig. 3A). The activity of Rac1 was also significantly lower in S-ATOR than in S-VEH (Fig. 3B). NAD(P)H oxidase activity and Rac1 activity did not significantly differ between W-ATOR and W-VEH (Fig. 3A, B).

Expression of Rac1, gp91^{phox}, and p22^{phox} in the Membrane Fraction and Rac1, p47^{phox}, and p40^{phox} in the Cytosolic Fraction

The expression of Rac1, gp91^{phox}, and p22^{phox} in the membrane fraction was significantly lower in S-ATOR than in S-VEH (Fig. 4A–C). The expression of p47^{phox} and p40^{phox} in the cytosolic fraction was also significantly lower in S-ATOR than in S-VEH (Fig. 5B, C). The expression of Rac1 in the cytosolic fraction was significantly higher, however, in S-ATOR than in S-VEH (Fig. 5A). The expression of Rac1, gp91^{phox}, and p22^{phox} in the membrane fraction and the expression of Rac1, p47^{phox}, and p40^{phox} in cytosolic fraction did not differ significantly between W-ATOR and W-VEH (Figs. 4A–C, 5A–C).

Cu/Zn- and Mn-SOD Activity in the RVLM

Mn-SOD activity in the RVLM was significantly higher in S-ATOR than in S-VEH, but Cu/Zn-SOD activity did not significantly differ between S-ATOR and S-VEH (Fig. 6A, B).


FIGURE 1. Time course of MBP (in mm Hg) (A) and HR (in beats per minute) (B) in S-ATOR (n = 5), S-VEH (n = 5), W-ATOR (n = 5), and W-VEH (n = 5). *P* < 0.05 for ATOR versus VEH values in each strain. C, D, Urinary norepinephrine excretion for 24 hours (in micrograms) (C) and LFnuSBP (percentage) (D) at day 14 in ATOR- or VEH-treated SHRSP or WKY (n = 5 for each). *P* < 0.05 for ATOR versus VEH values in each strain. †P < 0.05 compared with VEH-treated WKY. Data are shown as mean ± standard error of the mean.

© 2010 Lippincott Williams & Wilkins

FIGURE 2. TBARS levels (in micromolars per gram wet weight) in the RVLM at day 14 in ATOR- or VEH-treated SHRSP or WKY (n = 5 for each). *$P < 0.05$ for ATOR versus VEH in each strain. †$P < 0.05$ compared with VEH-treated WKY. Data are shown as mean ± standard error of the mean.

Cu/Zn- and Mn-SOD activity did not significantly differ between W-ATOR and W-VEH (Fig. 6A, B).

Microinjection of Apocynin Into the RVLM

The degree of the change in MBP induced by the microinjection of apocynin into the bilateral RVLM was significantly smaller in S-ATOR than in S-VEH (-9.4 ± 1.9 vs. -26.4 ± 3.7 mm Hg; n = 5; $P < 0.05$).

DISCUSSION

The novel finding of the present study was that atorvastatin administered chronically into the brain in SHRSP reduced BP and SNA in SHRSP and that it was associated with reduced oxidative stress, probably due to the inhibition of NAD(P)H oxidase and the activation of Mn-SOD in the RVLM of SHRSP. This is supported by the following findings: (1) ICV injection of atorvastatin for 14 days decreased MBP, HR, SNA, and TBARS in the RVLM of SHRSP; (2) ICV injection of atorvastatin decreased NAD(P)H oxidase activity

through the inhibition of Rac1 membrane translocation in the RVLM of SHRSP; (3) ICV injection of atorvastatin activated Mn-SOD in the RVLM of SHRSP; and (4) changes in MBP induced by microinjection of NAD(P)H oxidase inhibitor into the RVLM were significantly smaller in SHRSP treated with atorvastatin than in SHRSP treated with vehicle. Thus, atorvastatin inhibits Rac1 membrane translocation and Rac1 activity in the RVLM of SHRSP.

Atorvastatin decreased the expression of NAD(P)H membrane-bound subunits gp91[phox] and p22[phox] and the cytosolic regulatory subunit p47[phox] and p40[phox] and inhibited NAD(P)H oxidase activity in the RVLM of SHRSP. Oral administration of atorvastatin decreases ROS in the RVLM of SHRSP.[3] In the brain, ROS is produced mainly by NAD(P)H oxidase, which is activated through Rac1 membrane translocation.[11] In another area of the brainstem, the nucleus tractus solitarius, the inhibition of Rac1 decreases NAD(P)H oxidase activity and ROS formation.[12] Previous reports suggest that atorvastatin inhibits Rac1 membrane translocation and NAD(P)H oxidase activity in the vasculature of hypertensive rats.[13] We found that the depressor response elicited by apocynin into the RVLM was attenuated in SHRSP treated with ICV atorvastatin in the present study. Based on these findings, we suggest that the atorvastatin-induced reduction of ROS in the RVLM of SHRSP is caused by a decrease in NAD(P)H oxidase activity linked to the inhibition of Rac1 membrane translocation.

Atorvastatin activated Mn-SOD activity in the RVLM of SHRSP but not Cu/Zn-SOD. In the RVLM of SHRSP, Mn-SOD activity is decreased, and overexpression of Mn-SOD in the RVLM of SHRSP decreases ROS.[3] A number of reports suggest that statins activate total SOD[20–23] and Cu/Zn-SOD in the vasculature.[26,27] In the present study, however, atorvastatin did not activate Cu/Zn-SOD in the RVLM of SHRSP. In the nucleus tractus solitarius, Cu/Zn-SOD expression is decreased in SHRSP.[26] It is not clear why atorvastatin did not activate Cu/Zn-SOD in the present study. Recently, we reported that angiotensin II increases the intracellular Ca^{2+} concentration and that the increase in mitochondrial Ca^{2+} uptake leads to mitochondrial ROS production in the RVLM.[24] Therefore, it is possible that atorvastatin-induced activation of Mn-SOD in the RVLM of SHRSP contributes to inhibit ROS to an even greater extent than Cu/Zn-SOD.

FIGURE 3. NAD(P)H oxidase activity (A) and Rac1 activity (B), in the RVLM at day 14 in ATOR- or VEH-treated SHRSP or WKY (n = 5 for each). *$P < 0.05$ for ATOR versus VEH in each strain. †$P < 0.05$ compared with VEH-treated WKY. NAD(P)H oxidase or Rac1 activity was expressed relative to that in W-VEH, which was assigned a value of 1. Data are shown as mean ± standard error of the mean.